Publications @ the Saelens Group
- Schepens, B. et al. Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein. EMBO Mol Med 6, 1436–1454 (2014).
- Schotsaert, M. et al. Natural and long-lasting cellular immune responses against influenza in the M2e-immune host. Mucosal Immunology 6, 276–287 (2013).
- Verhelst, J. et al. Interferon-Inducible Protein Mx1 Inhibits Influenza Virus by Interfering with Functional Viral Ribonucleoprotein Complex Assembly. Journal of Virology 86, 13445–13455 (2012).
- Schepens, B. et al. Nanobodies® Specific for Respiratory Syncytial Virus Fusion Protein Protect Against Infection by Inhibition of Fusion. Journal of Infectious Diseases 204, 1692–1701 (2011).
- El Bakkouri, K. et al. Universal Vaccine Based on Ectodomain of Matrix Protein 2 of Influenza A: Fc Receptors and Alveolar Macrophages Mediate Protection. Journal of Immunology 186, 1022–1031 (2011).
- Neutralization of Junín virus by single domain antibodies targeted against the nucleoprotein.
- Vaccine options for influenza: thinking small.
- A Respiratory Syncytial Virus vaccine based on the Small Hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study.
- Potent anti-viral vaccine adjuvant based on pH-degradable nanogels with covalently linked small molecule imidazoquinoline TLR7/8 agonist.
- Corrigendum: Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.
- Transiently Thermoresponsive Acetal Polymers for Safe and Effective Administration of Amphotericin B as Vaccine Adjuvant.
- Clinical Potential of Prefusion RSV F-specific Antibodies.
- Oral delivery of Escherichia coli persistently infected with M2e-displaying bacteriophages partially protects against influenza A virus.
- Phosphoproteomics to Characterize Host Response During Influenza A Virus Infection of Human Macrophages.
- Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses.